Beyond the price war, Indian drug companies gearing up to win the GLP-1 retention game

semaglutide

• 50+ generic semaglutide brands to launch in India by March 2026
• Prices expected at one-third to one-fifth of innovator's cost
• Drugmakers emphasize patient support and ecosystem differentiation

Did our AI summary help?

More than 50 generic brands are expected to enter the Indian market within weeks as semaglutide, a major GLP-1 therapy, moves beyond its period of exclusivity in mid-March 2026.

The sudden transition, for a market previously defined by scarcity to absolute abundance is triggering an aggressive price war, with new entrants expected to offer the blockbuster GLP-1 therapy at a fraction of the innovator’s cost.

Industry analysts say the arrival of these affordable alternatives—expected to be priced at one-third to one-fifth of the innovator's cost.

With over 100 million people suffering from Type-2 Diabetes and 135 million estimated to be overweight or obese, India offers huge market opportunity for a drug that is considered considered potentially "disease-modifying", as they go beyond managing symptoms to alter underlying disease conditions such as cardiovascular diseases, improving renal function, reducing neuroinflammation in neurodegenerative diseases, and showing promise in treating obesity-related inflammation and osteoarthritis.

According to data from the Indian Pharmaceutical Market (IPM), the anti-diabetic therapy segment has already seen a 15.5 percent value growth in early 2026, driven largely by new product introductions. The arrival of dozens of affordable alternatives is expected to accelerate this trend, shifting the market from premium exclusivity to broad physician adoption.

Indian drugmakers have intensified their efforts to prime the market before the launch, which include reaching out to doctors and building awareness.

“We conducted extensive assessments to understand gaps at both the doctor and patient levels—awareness gaps, challenges with dose titration, side effects, and what happens when patients plateau," M.V. Ramana, CEO – Branded Markets (India & Emerging Markets), Dr. Reddy’s Laboratories. Dr.Reddy's will be launching generic version of Ozempic (semaglutide) on March 21st.

"To address these, we are working with international obesity societies, setting up Obesity Centres of Excellence across India, and building structured patient‑management programs. We are going beyond the pill with onboarding support, titration guidance and nutritional solutions,” Ramana added.

Other pharmaceutical companies such as Sun Pharma, Mankind Pharma, Lupin, Zydus Lifesciences, Alkem Laboratories, Intas Pharmaceuticals, and Eris Lifesciences, among others are also gearing up to enter or scale their presence in the expanding GLP‑1 segment, reflecting a broader industry shift toward addressing lifestyle-led non‑communicable diseases (NCDs) that are emerging in India almost a decade earlier than in Western populations.

Priming the market

To navigate a market where dozens of brands may launch simultaneously with similar "Sema" prefixes, manufacturers are moving beyond simple molecule promotion toward "ecosystem-led differentiation.

Stakeholder feedback by Pronto Consult indicates that 72 percent of physicians anticipate naming similarities will lead to significant recall confusion. Consequently, companies are priming the market through several strategic levers like introducing month-long bundled packs and tiered pricing models to reach various socio-economic segments; new launches are being supported by "Dose Escalation Starter Kits" and "QR-enabled digital onboarding" to assist with patient treatment, and drugmakers are also focusing on long-term patient retention through support programs and institutional partnerships.

Analysis of the IPM underscores that while acute therapies remain volume-driven, the value-driven growth in the chronic segment will be accelerated by such off-patent opportunities and the rising incidence of non-communicable diseases.

The competitive focus is shifting from the initial prescription to long-term patient refills.

Because semaglutide requires ongoing management, the market winners will be those who can provide a consistent and reliable supply.

"The winners of the Semaglutide era will not simply be those who launch first or have the lowest price," says Hari Natarajan of Pronto Consult.

"The winners will be those who convert a crowded molecule into a trusted therapy experience. Because in the end, while molecules create markets, it is trust that creates leaders," he added.

Data from Pharmarack highlights that while acute therapies remain volume-driven, the value-driven growth in the chronic segment will be accelerated by these off-patent opportunities.

While Eli Lilly’s Tirzepatide (Mounjaro) initially held an early-mover advantage in the injections market, recent data shows that semaglutide (Ozempic/Wegovy) has picked up significant momentum, with incremental consumption recently outpacing its rival.